News
2.11.23

TOPADUR, Yonsei University and Juvic Inc. grant awarded

Zurich-Schlieren, Switzerland, 2 November 2023

We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.

Download DocumentDokument herunterladen
27.6.22
News

Scientific Publication in the International Journal of Molecular Sciences

A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.

Read more
5.1.24
Press Release

Topadur Pharma AG receives an innosuisse grant

CHF 1.76 million is awarded from Innosuisse for the Phase 2a clinical trial with TOP-N53 in the treatment of digital ulcers

Read more
24.10.24
News

Topadur Pharma AG announces CEO change

The Board of Directors of Topadur Pharma AG announces that Pascal Brenneisen will leave his position as CEO

Read more